Stockscreener 앱 받기
7.04
0.28%
-0.02
시간 외 거래:
7.04
전일 마감가:
$7.06
열려 있는:
$6.79
하루 거래량:
2.85M
Relative Volume:
1.13
시가총액:
$1.12B
수익:
$405.76M
순이익/손실:
$7.98M
주가수익비율:
140.80
EPS:
0.05
순현금흐름:
$77.47M
1주 성능:
-0.14%
1개월 성능:
-1.81%
6개월 성능:
-35.77%
1년 성능:
-39.98%
1일 변동 폭
$6.7475
$7.15
1주일 범위
$6.7475
$7.52
52주 변동 폭
$6.04
$15.38
Certara Inc Stock (CERT) Company Profile
명칭
Certara Inc
전화
(415) 237-8272
주소
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, TEM, BTSG, HQY, MMED
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
7.04 | 1.12B | 405.76M | 7.98M | 77.47M | 0.05 |
|
VEEV
Veeva Systems Inc
|
195.57 | 32.14B | 3.08B | 860.33M | 1.35B | 5.1463 |
|
TEM
Tempus Ai Inc
|
52.32 | 9.34B | 1.27B | -245.03M | -245.36M | -1.4071 |
|
BTSG
Brightspring Health Services Inc
|
42.23 | 8.03B | 11.99B | 24.18M | 234.31M | 0.2956 |
|
HQY
Healthequity Inc
|
80.04 | 6.69B | 1.15B | 96.70M | -161.99M | 1.09 |
|
MMED
Minimed Group Inc
|
18.00 | 5.19B | 0 | 0 | 0 | 0.00 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-21 | 개시 | Rothschild & Co Redburn | Buy |
| 2025-11-13 | 개시 | BMO Capital Markets | Market Perform |
| 2025-09-29 | 개시 | Craig Hallum | Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2025-05-08 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2025-02-27 | 개시 | TD Cowen | Buy |
| 2024-09-27 | 업그레이드 | UBS | Neutral → Buy |
| 2024-04-10 | 업그레이드 | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | 개시 | JMP Securities | Mkt Perform |
| 2024-02-26 | 개시 | Leerink Partners | Market Perform |
| 2023-12-07 | 개시 | UBS | Neutral |
| 2023-12-05 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-08-10 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | 개시 | Stephens | Overweight |
| 2023-04-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2022-12-14 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | 개시 | Berenberg | Buy |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-07-01 | 개시 | Piper Sandler | Overweight |
| 2022-01-11 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-08-05 | 재개 | Credit Suisse | Neutral |
| 2021-07-23 | 개시 | Robert W. Baird | Outperform |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-01-06 | 개시 | Morgan Stanley | Equal-Weight |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Credit Suisse | Neutral |
| 2021-01-05 | 개시 | Jefferies | Hold |
| 2021-01-05 | 개시 | William Blair | Outperform |
모두보기
Certara Inc 주식(CERT)의 최신 뉴스
Certara at Leerink Conference: Strategic Moves Amid Challenges - Investing.com
How Investors Are Reacting To Certara (CERT) FDA Acceptance Of Simcyp In Place Of Clinical Trials - simplywall.st
Certara CEO Resnick Teases Regulatory Services Decision, Phoenix Cloud Push at TD Cowen Conference - Yahoo Finance
Certara appoints Jon Resnick as new CEO; reaffirms FY25 outlook - MSN
Will Certara Inc. stock outperform international peers2025 EndofYear Setup & Short-Term Trading Alerts - Naître et grandir
CERTCertara Inc Stock Price and Quote - Finviz
Certara, Inc. (CERT): Analysts Assign Equal-Weight Rating Amid Price Stagnation - 富途牛牛
Certara (CERT) Downgraded to Equal-Weight by Barclays | CERT Sto - GuruFocus
Forecasting The Future: 7 Analyst Projections For Certara - Benzinga
Barclays downgrades Certara stock rating on turnaround concerns By Investing.com - Investing.com South Africa
Barclays downgrades Certara stock rating on turnaround concerns - Investing.com India
Certara at TD Cowen Conference: Strategic Focus and AI Integration By Investing.com - Investing.com Canada
Certara (CERT) Gains FDA Acceptance for PBPK Modeling in Drug Ap - GuruFocus
Certara, Inc. (CERT) Stock Analysis: Exploring a 38% Potential Upside in Health Information Services - DirectorsTalk Interviews
CERT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Certara Simcyp® simulator results replace ten human trials for chronic myeloid leukemia (CML) therapy asciminib - marketscreener.com
Certara Simcyp Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - Bitget
Certara Simcyp® Simulator Results Replace Ten Human Trials for Chronic Myeloid Leukemia (CML) Therapy asciminib - The Manila Times
FDA accepts virtual-patient data so leukemia drug avoids 10 trials - Stock Titan
Certara, Inc. $CERT Stock Holdings Boosted by Roubaix Capital LLC - MarketBeat
Certara Earnings Call: Software Strength Amid Transition - The Globe and Mail
Certara (CERT) director granted 5,547 restricted stock units - Stock Titan
Certara (CERT) director Arjun Bedi submits initial Form 3 insider filing - Stock Titan
Certara (CERT) Is Up 9.6% After Calling 2026 a Transition Year With Slower Growth Guidance - simplywall.st
Assessing Certara (CERT) Valuation After Recent Share Price Volatility - Yahoo Finance
Discipline and Rules-Based Execution in CERT Response - Stock Traders Daily
A Look At Certara (CERT) Valuation After Earnings Miss And 2026 Outlook Reset - simplywall.st
Certara, Inc. Hits 52-Week Low at USD 6.04 Amid Market Struggles - Markets Mojo
Certara (NASDAQ:CERT) Trading 6.1% HigherHere's What Happened - MarketBeat
Certara (CERT) Faces Downgrade Amid Strategic Uncertainty - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Barclays - MarketBeat
Certara stock downgraded at Craig-Hallum on growth concerns By Investing.com - Investing.com Canada
Certara stock downgraded at Craig-Hallum on growth concerns - Investing.com
Certara (NASDAQ:CERT) Rating Lowered to "Hold" at Craig Hallum - MarketBeat
Drug development firm Certara lines up three March investor talks - Stock Titan
Morgan Stanley Cuts Price Target on Certara to $11 From $12, Keeps Equalweight Rating - marketscreener.com
Leerink cuts Certara stock price target on weak bookings, guidance By Investing.com - Investing.com India
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara Q4 2025 slides: services growth offsets software weakness By Investing.com - Investing.com Australia
Certara stock hits 52-week low at 6.26 USD By Investing.com - Investing.com Australia
Certara (NASDAQ:CERT) Issues Earnings Results - MarketBeat
Leerink Maintains Outperform on Certara, Inc. (CERT) Feb 26 2026 PT $10 - Meyka
Certara to Participate in Upcoming Investor Conferences - Bitget
Certara Inc reports results for the quarter ended December 31Earnings Summary - TradingView
TD Cowen cuts Certara stock price target on macro headwinds By Investing.com - Investing.com India
TD Cowen cuts Certara stock price target on macro headwinds - Investing.com
Certara outlines flat to 4% 2026 revenue growth as new CEO signals operational overhaul and $10M cost avoidance - MSN
Leerink cuts Certara stock price target on weak bookings, guidance - Investing.com
Certara Q4 2025 slides: services growth offsets software weakness - Investing.com
Certara Q4 Earnings Call Highlights - MarketBeat
CERT: 2026 guidance targets flat to 4% revenue growth amid operational changes and AI-driven focus - TradingView
Certara Inc (CERT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.48%
0.33%
자본화:
|
볼륨(24시간):